Has Christine Cain received payments from drug or device companies?

Yes. Drug and device makers reported $6,161 in general payments to Christine Cain across 230 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Christine Cain did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Christine Cain come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Christine Cain

Hematology & Oncology · Merrillville, INNPI 1396423976

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,469 of the $6,161 with a category attached, or 88.8%. It is spread thinly across 51 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,094, 4.7 times the $664 reported in 2023.

$6,161in general payments, 2019–2025

Across 230 payments — averaging $26.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$995
AstraZeneca$624
Pfizer$429
Johnson & Johnson$407
E.r. Squibb & Sons, L.L.C.$270
Gilead$262
plus $3K from 45 others

What the payments were for

Food & beverage$5,46989%
Education$2935%
Other$3996%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	32	$995
AstraZeneca(2 entities)	23	$624
Pfizer	21	$429
Johnson & Johnson(2 entities)	12	$407
E.r. Squibb & Sons, L.L.C.	11	$270
Gilead(2 entities)	4	$262
Daiichi Sankyo Inc.	10	$251
AbbVie	10	$193
Merck	7	$168
Ipsen Biopharmaceuticals, Inc	2	$165
Sumitomo Pharma America, Inc.	6	$147
AVEO Pharmaceuticals, Inc.	3	$143
Adaptive Biotechnologies Corporation	5	$131
Incyte Corporation	6	$120
Caris MPI, Inc.	4	$119
Genentech USA, Inc.	5	$114
Pharmacosmos Therapeutics Inc.	5	$114
Sanofi	5	$105
Springworks Therapeutics, Inc.	3	$91
Astellas Pharma US Inc	3	$90
Regeneron Healthcare Solutions, Inc.	3	$90
Array Biopharma Inc	4	$86
Pharmaessentia USA Corporation	4	$84
Takeda Pharmaceuticals U.S.A., Inc.	3	$73
Tactile Systems Technology Inc	2	$56
Stemline Therapeutics Inc.	3	$55
ASD Specialty Healthcare, LLC	1	$54
Deciphera Pharmaceuticals Inc.	2	$54
Puma Biotechnology, Inc.	3	$53
Beone Medicines USA, Inc.	2	$52
Exelixis Inc.	2	$52
Beigene USA, Inc.	2	$41
Tempus AI, Inc	2	$38
Rigel Pharmaceuticals, Inc.	2	$34
Sobi, Inc	2	$34
Pharming Healthcare, Inc.	1	$32
Blueprint Medicines Corporation	1	$30
Jazz Pharmaceuticals Inc.	1	$29
Lilly USA, LLC	1	$26
Stryker	1	$26
Servier Pharmaceuticals LLC	1	$25
Accord Healthcare, Inc.	1	$24
CTI Biopharma Corp.	1	$24
Eisai Inc.	1	$23
Mirati Therapeutics, Inc.	1	$22
GSK	1	$21
Acrotech Biopharma Inc.	1	$20
Coherus Oncology, Inc.	1	$17
Alnylam Pharmaceuticals Inc.	1	$17
Morphosys, US Inc.	1	$16
ADC Therapeutics America, Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ONIVYDE$140
Trodelvy$125

How this compares

$6,161 in reported general payments places this provider in the 55th percentile of 224 hematology & oncology providers in Indiana.

See all hematology & oncology providers in Indiana →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Anastrozole	38	$694
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	19	$490
Warfarin Sodium	46	$179
Allopurinol	11	$47

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Merrillville

Geeta KurraMerrillville$76K
Bharat BaraiMerrillville$30K
Richard GaynorIndianapolis$3.7M
Ruemu BirhirayIndianapolis$3.1M
Chandler ParkCorydon$661K
Neel ShahDyer$464K
Ahad SadiqFort Wayne$430K
Ajay KandraMadison$408K
Anand TandraIndianapolis$280K
Attaya SuvannasankhaIndianapolis$253K

See the full list for Indiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →